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ABSTRACT: 38 
Background: Associations between dietary fats and mortality are unclear. 39 
Methods: We evaluated the relationship between quartiles of total fat, mono-unsaturated (MUFA), 40 
polyunsaturated (PUFA) and saturated fatty acid (SFA) consumption, and all-cause, coronary heart 41 
disease (CHD), stroke, and type 2 diabetes (T2D)-associated mortality in 24,144 participants from 42 
the National Health and Nutrition Examination Surveys (NHANES) 1999-2010. 43 
We added our results to a meta-analysis based on searches until November 2018.  44 
Results: In fully adjusted Cox-proportional hazard models in our prospective study, there was an 45 
inverse association between total fat (HR: 0.90, 95% confidence interval 0.82, 0.99, Q4 vs Q1) and 46 
PUFA (0.81, 0.78-0.84) consumption and all-cause mortality, whereas SFA were associated with 47 
the increased mortality (1.08, 1.04-1.11). In the meta-analysis of 29 prospective cohorts 48 
(n=1,148,117) we found a significant inverse association between total fat (0.89, 0.82-0.97), 49 
MUFA (0.93, 0.87-0.99) and PUFA (0.86, 0.80-0.93) consumption and all-cause mortality. No 50 
association was observed between total fat and CVD (0.92, 0.79-1.08) or CHD mortality (1.03 51 
0.99-1.09). A significant association between SFA intake and CHD mortality (1.10, 1.01-1.20) 52 
was observed. Neither MUFA nor PUFA were associated with CVD or CHD mortality. Inverse 53 
associations were observed between MUFA (0.80, 0.67-0.96) and PUFA (0.84, 0.80-0.90) intakes 54 
and stroke mortality. 55 
Conclusions: We showed differential associations of total fat, MUFA and PUFA with all-cause 56 
mortality, but not CVD or CHD mortalities. SFA was associated with higher all-cause mortality 57 
in NHANES and with CHD mortality in our meta-analysis. The type of fat intake appears to be 58 
associated with important health outcomes. 59 
 60 
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Cardiovascular disease (CVD) remains the leading cause of mortality worldwide 1, and CVD 68 
accounts for over 17 million deaths annually with almost 1 million deaths in the US 1. Similarly, 69 
the prevalence of type 2 diabetes (T2D) is rapidly increasing all over the world with a predicted 70 
592 million cases by 2035 2. Diet is one of the most important modifiable risk factors for CVD and 71 
current guidelines recommend a low-fat diet and substantial limiting of saturated fatty acids (SFA) 72 
while increasing intake of unsaturated fatty acids – both monounsaturated (MUFAs) and 73 
polyunsaturated fatty acids (PUFAs) 3.  74 
The effects of different types of dietary fat on health have long been of interest. This dietary 75 
strategy attracts considerable controversy and has been investigated in epidemiological and clinical 76 
studies. Results from relatively old meta-analyses did not support the association of SFAs with all-77 
cause, CVD, or T2D mortality 4-6. In the European Prospective Investigation into Cancer and 78 
Nutrition-Netherlands cohort study the authors evaluated SFA intake and coronary heart disease 79 
(CHD) with 12-year follow-up 7. Higher SFA intake was not associated with higher CHD risk 7. 80 
Conflicting results were obtained in another study where higher dietary intakes of major SFAs 81 
were significantly associated with an increased risk of CHD 8. In fact, there are several studies in 82 
the medical literature with contradictory findings regarding the potential role of dietary fats on 83 
hard health outcomes.  84 
In 2017, after a review of the existing evidence, the American Heart Association (AHA) 85 
endorsed the recommendation to reduce intake of SFA and replace it with unsaturated fats, 86 
especially PUFA, in order to reduce the incidence of CVD 9. This was based on several studies 87 
reporting PUFA intake to be associated with lower all-cause and CVD mortality 10, 11. However, 88 
there are also studies which did not demonstrate a significant link between PUFA intake and risk 89 
of all-cause mortality 12, 13, including very recent randomized controlled trials (RCTs), which 90 
showed no effect of PUFA supplementation on CVD events 14, 15. The recent 18-country 91 
observational Prospective Rural Urban Epidemiology (PURE) study suggested that total fat and 92 
types of fat were related to lower all-cause mortality. Total fat and types of fat were not associated 93 
with CVD, myocardial infarction (MI), or CVD mortality, whereas saturated fat had an inverse 94 
association with stroke 16. However, the results in PURE may be confounded by poverty in some 95 
regions and the results do not apply to high-income countries, where diets are vastly different.  96 
Intake of MUFAs has been reported to improve blood lipid profiles, inflammatory markers, 97 
and common CVD risk factors, but little evidence exists to associate consumption of MUFAs with 98 
lower CVD mortality 17-19. In a recent study performed among 63,442 women from the Nurses’ 99 
Health Study and 29,942 men from the Health Professionals Follow-Up Study, the authors reported 100 
no link between MUFA intake and CHD mortality 20. In another study, the associations of specific 101 
dietary fats with all-cause and cause-specific mortality were examined, and hazard ratios (HRs) 102 
for all-cause mortality comparing extreme quintiles of specific dietary fats were 1.08, (95%CI, 103 
1.03-1.14) for SFA, 0.81 (0.78-0.84) for PUFA and 0.89 (0.84-0.94) for MUFA 21. 104 
Based on the available data, the associations between different fats with mortality still appear 105 
to be conflicting. Public concerns have increasingly been raised regarding the link between higher 106 
SFA intake and the prevalence of various chronic disorders 22, 23. Therefore, it is still unclear which 107 
types of fat should be promoted to improve health outcomes. To address these concerns, we 108 
examined the association between fat consumption (total, MUFA, PUFA, SFA) and all-cause and 109 
cause-specific (CHD, stroke and T2D) mortality in a large, nationally representative US cohort. 110 
Furthermore, we performed a comprehensive systematic review and meta-analysis to examine 111 
these possible associations by using all existing prospective cohort studies. 112 
 113 
METHODS 114 
[A] NHANES study 115 
Population:  116 
This was a prospective cohort study using data from the US National Health and Nutrition 117 
Examination Survey (NHANES 1999-2010). The National Center for Health Statistics (NCHS) 118 
Research Ethics Review Board approved the underlying protocol, and written informed consent 119 
was obtained from all participants. Details on NHANES Laboratory/Medical Technologists 120 
Procedures and Anthropometry Procedures have been described elsewhere 24, 25.  121 
Baseline data in NHANES were gathered when individuals participated in a household 122 
interview and a medical examination, during which they provided blood and urine samples. 123 
Demographic information, including sex, age, ethnic origin, household income, education, and 124 
smoking status was obtained during the household interview (26). A digital scale was used to 125 
measure weight to the nearest 100 g and a fixed stadiometer to measure height to the nearest mm. 126 
Body mass index (BMI) was calculated as weight in kg divided by the square of height in m. Waist 127 
circumference (WC) was measured at the iliac crest to the nearest mm, using a steel tape 26. A 128 
blood specimen was drawn from the participant’s antecubital vein. Fasting blood glucose (FBG) 129 
was measured by a hexokinase method using a Roche/Hitachi 911 Analyzer and Roche Modular 130 
P Chemistry Analyzer (NJ, USA). Other laboratory-test details are available in the NHANES 131 
Laboratory/Medical Technologists Procedures Manual 27. Details on C-reactive protein (CRP) 132 
measurement are available elsewhere 26. Hypertension (HTN) was diagnosed in individuals with 133 
SBP ≥140 mmHg and/or DBP ≥90 mmHg, and in participants on antihypertensive medications 28. 134 
T2D was defined as a self-reported history of diabetes or fasting blood glucose (FBG) ≥126 mg/dL 135 
29. 136 
Dietary intake was assessed via 24h recall obtained by a trained interviewer, with the use of a 137 
computer-assisted dietary interview system with standardized probes, i.e. the United States 138 
Department of Agriculture Automated Multiple-Pass Method (AMPM) 30, 31. Briefly, the type and 139 
quantity of all foods and beverages consumed in a single 24h period before the dietary interview 140 
(from midnight to midnight) were collected using the AMPM. The AMPM is designed to enhance 141 
complete and accurate data collection while reducing respondent burden 31, 32. In the current study 142 
we used the data on fatty acids intake such as total daily fat intake, total SFA intake (the sources 143 
of SFA in the diet have been described previously 33), total MUFA intake and total PUFA intake, 144 
saturated fatty acids (SFA) 4:0 (butanoic), SFA 6:0 (hexanoic), SFA 8:0 (octanoic), SFA 10:0 145 
(decanoic), SFA 12:0 (dodecanoic), SFA 14:0 (tetradecanoic), SFA 16:0 (hexadecanoic), SFA 146 
18:0 (octadecanoic), MUFA 16:1 (hexadecenoic), MUFA 18:1 (octadecenoic), MUFA 20:1 147 
(eicosenoic), MUFA 22:1 (docosenoic), PUFA 18:2 (octadecadienoic), PUFA 18:3 148 
(octadecatrienoic), PUFA 18:4 (octadecatetraenoic), PUFA 20:4 (eicosatetraenoic), PUFA 20:5 149 
(eicosapentaenoic), PUFA 22:5 (docosapentaenoic) and PUFA 22:6 (docosahexaenoic). 150 
 151 
Mortality: 152 
A full description of mortality linkage methods is available from the National Center for 153 
Health Statistics (NCHS). The anonymized data of NHANES 1999-2010 participants were linked 154 
to longitudinal Medicare and mortality data using the NHANES assigned sequence number. 155 
Mortality follow-up data are available from the date of survey participation until December 31, 156 
2011 (median follow-up: 12 years). We examined all-cause mortality, as well as mortality due to 157 
CHD (I00-I09, I11, I13, I20-I51), cerebrovascular disease (I60-I69), and diabetes (E10-E14). 158 
Cause of death was determined using ICD-10.  159 
 160 
Statistical analysis:  161 
Analyses were conducted according to the guidelines set by the Centers for Disease Control 162 
(CDC) and Prevention for analysis of the NHANES dataset, accounting for the masked variance 163 
and using their suggested weighting methodology 34. Continuous and categorical demographic 164 
variables were compared across total fat consumption quartiles using analysis of variance 165 
(ANOVA) and Chi-square tests, respectively.  166 
We constructed Kaplan-Meier survival curves according to quartiles of total fat intake 167 
compared differences for the composite endpoint (all-cause mortality) across groups using the log-168 
rank test. Multivariable Cox proportional hazards were applied to determine the HRs and 95% 169 
confidence intervals (95% CIs) of mortality (all-cause, CHD, CVD, T2D and cerebrovascular) for 170 
total fat, MUFA, PUFA, SAF consumption; the first quartile (Q1) was always used as reference. 171 
To derive the HR and 95%CI we performed analyses using 2 different models, Model 1: adjusted 172 
for age, race, education, marital status, poverty to income ratio, total energy intake, physical activity 173 
and smoking; Model 2: additionally adjusted for alcohol consumption, dietary cholesterol, body 174 
mass index, hypertension, and non-HDL cholesterol. The Cox regression was applied for the 175 
second model (adjusted for age, race, education, marital status, poverty to income ratio, total energy 176 
intake, physical activity, smoking, alcohol consumption, dietary cholesterol, body mass index, 177 
hypertension, and non-HDL cholesterol), to have same covariates with same outcomes (all-cause, 178 
CHD, stroke and T2D death).   179 
A two-sided p<0.05 was used to characterise significant results. All statistical analysis was 180 
conducted in R (version 3.4.2 R Core Team, 2017), Comprehensive Meta-Analysis V3 software 181 
(Biostat 2014, Englewood, NJ) and SPSS® complex sample module version 22.0 (IBM Corp, 182 
Armonk, NY). 183 
 184 
[B] Systematic Review and Meta-Analysis 185 
Literature search and study selection: 186 
The meta-analysis was designed, conducted and reported according to Meta-analysis Of 187 
Observational Studies in Epidemiology (MOOSE) guidelines 35. The primary exposures of interest 188 
were fat type consumption and various sub-types, whereas the primary outcomes were all-cause 189 
and cause-specific mortality. Prospective cohort studies published up to 31 November 2018, 190 
without language restriction, were searched using PubMed, SCOPUS, Web of Science and Google 191 
Scholar databases. The query syntax of searching is shown in the Supplemental Methods 192 
(Supplemental Table 1). This was complemented by hand searches of the reference list of eligible 193 
articles, and email correspondence with authors for additional relevant data. After excluding 194 
duplicates and based on titles and abstracts, we excluded studies on animals, baseline age <20 195 
years, or populations with prior CHD, T2D or any other chronic disease. In addition, 196 
supplementary hand searching of reference lists of previous reviews or meta-analyses was 197 
conducted.  198 
 199 
Study Selection: 200 
Study selection started with the removal of duplicates, followed by screening of titles and 201 
abstracts by 2 reviewers (MM and MB). To avoid bias, the reviewers were blinded to the names, 202 
qualifications or institutional affiliations of the study authors. The agreement between the 203 
reviewers was excellent (Kappa index: 0.92; p<0.001). Disagreements were resolved at a meeting 204 
between reviewers and third reviewer (DPM) prior to selected articles being retrieved (a flow chart 205 
is available in Supplemental Figure 1).  206 
We included studies if they met all the following criteria: (1) evaluated fat intake, (2) were 207 
population-based cohort studies and reported mortality data, and, (3) relative risk (RR), HR or 208 
odds ratio (OR) estimates with 95%CIs adjusted for multivariable factors were available or could 209 
be calculated. Studies were excluded according to the following criteria: (1) reviews, letters, 210 
unpublished data or comments, (2) those published in languages other than English, (3) not 211 
population-based cohort studies, and, (4) RR or HR estimates with 95%CI were not available or 212 
could not be calculated (despite individual contact attempts with the given investigators). Narrative 213 
reviews, comments, opinion pieces, editorials, letters or any other publications lacking primary 214 
data and/or explicit method descriptions, were also excluded.  215 
 216 
Data extraction and management: 217 
Full text of studies meeting inclusion criteria were retrieved and screened to determine 218 
eligibility by two reviewers (MM, NK). The study quality assessment was performed according to 219 
the Newcastle-Ottawa Scale (NOS, Supplemental Table 2) 36. By evaluation of selection, 220 
comparability and outcome, the rating system scores studies from 0 (highest degree of bias) to 9 221 
(lowest degree of bias). Additionally, we investigated the funding sources of the eligible studies. 222 
Following assessment of methodological quality, two reviewers (MM, MB) extracted data using a 223 
purpose-designed data extraction form. Information extracted per study included: author, year and 224 
references, country, study name, age, follow-up time (years), number of cases, and number of 225 
participants, exposure categories, outcome and main confounders. Extractions were compared and 226 
any differences of opinion were resolved by discussion and consultation with a third reviewer 227 
(DPM). Any further calculations on study data considered necessary, was conducted by the first 228 
reviewer (MM) and checked by the second reviewer (MB).  229 
 230 
Data synthesis and statistical analyses: 231 
For studies that reported results from different multivariable-adjusted models, the model with 232 
the most confounding factors was extracted for the meta-analysis. DerSimonian-Laird method or 233 
generic inverse variance methods were used for random effects meta-analyses to calculate pooled 234 
HRs, 95%CI and p value for heterogeneity. HRs comparing the highest score category with the 235 
lowest category were combined across studies to generate the summary associations. The extent 236 
of heterogeneity across studies was examined using the I2 test 37-39; an I2 >50% together with a 237 
two-sided p<0.05 indicated significant heterogeneity 37-39.  238 
 239 
Publication bias: 240 
Potential publication bias was explored using Begg’s rank correlation and Egger’s weighted 241 
regression tests. Duval and Tweedie ‘trim and fill’ method was used to adjust the analysis for the 242 
effects of publication bias 40. Meta-analyses were conducted using the Comprehensive Meta-243 
Analysis (CMA) V3 software (Biostat, NJ) 41. 244 
 245 
RESULTS 246 
[A] NHANES study  247 
Overall, 24,144 participants were included (mean age was 49.6 years and 48.5% were men). 248 
Their demographic characteristics according to total fat intake quartiles are shown in Table 1. 249 
Participants in the highest quartile of total fat were significantly younger than those in the lowest 250 
quartile (40.0 vs 54.8, p<0.001, Table 1). For the lowest category of fat consumption, females 251 
were in the majority, while males were in the majority in the highest category (p<0.001, Table 1). 252 
We found the following crude reported mean and SEM (g/day) for intake of total fat 253 
(overall=78.7±0.3, males=90.2±0.5 vs females=66.2±0.4; p<0.001), PUFA (overall=16.8±0.8, 254 
males=19.2±0.4 vs females=14.1±0.5; p<0.05), MUFA (overall=28.6±0.1, male=33.1±0.2 vs 255 
female=23.1±0.2; p<0.05), and SFA (overall=25.6±0.1, males=29.5±0.1 vs females=21.4±0.1; 256 
p<0.001). 257 
During the follow-up of up to 12 years of NHANES 1999-2010, 3,632 all-cause deaths were 258 
recorded, including 714 CHD-related deaths and 233 due to stroke. Kaplan-Meier survival plots 259 
showed that subjects in the highest quartiles of total fat intake had significantly lower all-cause 260 
mortality than those in the lowest quartiles (log-rank p<0.0001; Figure 1 & Central Illustration). 261 
Results from multivariable Cox regression models for risk of death across fat quartiles are 262 
shown in Table 2. With regard to total fat, in Model 1, subjects with the highest consumption had 263 
a 16% lower risk of mortality (HR: 0.84, 95%CI: 0.81, 0.88); this association was diluted but was 264 
still significant in Model 2 (HR: 0.90, 95%CI: 0.82, 0.99, Table 2, Central Illustration). In the 265 
Model 1, subjects in the highest quartile had 12% lower risk for CHD mortality (HR: 0.88, 95%CI: 266 
0.86, 0.89, Table 2), while this association was no longer evident after further adjustments in 267 
Model 2 (p=0.421 for trend; Central Illustration). We did not find significant association between 268 
intake of total fat and both stroke and T2D mortality in both models (p>0.365, Table 2).  269 
With regard to SFA intake, increase in risk of all-cause mortality was observed for both the 270 
1st and 2nd model (Model 2=Q2: 1.05, 95%CI: 1.02, 1.08; Q3: 1.14, 95%CI: 1.10, 1.19, Q4: 1.08, 271 
95%CI: 1.04, 1.11, Table 2, Central Illustration). We observed that subjects in the highest 272 
quartile (Q4) of the SFA had significantly higher risk of CHD mortality even after adjustment for 273 
wide range of co-variables (HR: 1.11, 95%CI: 1.07, 1.17, Table 2, Central Illustration). In Model 274 
2, subjects in the highest quartile had a 13 and 4% greater risk of stroke (HR: 1.13, 95%CI: 1.06, 275 
1.22) and T2D (HR: 1.04, 95%CI: 1.01, 1.08) mortality, respectively, compared with the first 276 
quartile (Q1).  277 
With regard to MUFA, we found that (Model 1) subjects in the highest quartile had a 278 
significantly lower risk of all-cause mortality compared with the first quartile (Q2: 1.02, 95%CI: 279 
0.29, 3.96; Q3: 0.85, 95%CI: 0.80, 0.91, and Q4: 0.71, 95%CI: 0.69, 0.74, Table 2, Central 280 
Illustration). However, no significant association was observed for this outcome in the fully 281 
adjusted Model 2. Further, either in the partially or fully adjusted model we observed insignificant 282 
association between CHD, stroke and T2D mortalities with MUFA intake (Table 2).  283 
With regard to PUFA intake, we observed a protective association with all-cause mortality in 284 
both minimally and fully adjusted model - in the Model 2 subjects in the highest quartile had 19% 285 
lower risk of all-cause mortality (HR: 0.81, 95%CI: 0.78-0.84, Table 2, Central Illustration). 286 
Further, subjects in the highest quartile of PUFA intake in both in first and second model had a 43 287 
and 25% lower risk of CHD mortality (Model 1= Q4: 0.57, 95%CI: 0.55, 0.60; Model 2 = Q4: 0.75, 288 
95%CI: 0.62-0.90, Table 2, Central Illustration). Similar inverse associations were observed in 289 
both models for both stroke and T2D mortality - in the fully adjusted model, subjects in the highest 290 
quartile of PUFA both had 15 and 14% lower risk of stroke and T2D mortality (0.85, 95%CI: 0.80-291 
0.91; and 0.84, 95%CI: 0.79-0.92, respectively; Table 2).  292 
 293 
[B] Meta-Analysis 294 
Of 49 eligible full articles, 29 cohorts met the inclusion criteria (Supplemental Figure 1). An 295 
overview of key characteristics of the 29 prospective cohort studies is shown in Supplemental 296 
Table 3. A total of 1,148,117 participants, with 253,592 deaths, were included in the analysis. The 297 
duration of follow-up ranged from 3.7 to 32.0 years (mean= 13.3 years [156 months]). Results of 298 
NOS quality assessment are shown in the Supplemental Table 2, with seven studies scoring 8, 299 
and no study scoring less than 7.  300 
 301 
Total fat consumption and all-cause and cause-specific mortality: 302 
We found an inverse and significant association between total fat consumption and all-cause 303 
mortality (HR: 0.89, 95%CI: 0.82-0.97, p=0.009, n=11 studies, I2: 27%, Figure 2, Central 304 
Illustration). No significant association was observed between total fat with both CVD and CHD 305 
mortality (HR: 0.92, 95%CI: 0.79-1.08, p=0.340, n=8 studies, I2: 46%, Supplemental Figure 2, 306 
and HR: 1.03, 95%CI: 0.99-1.09, p=0.115, n=7 studies, I2: 42%, respectively; Central 307 
Illustration).   308 
We observed a non-significant association between SFA and all-cause mortality (HR: 1.04, 309 
95%CI: 0.98-1.11, p=0.139, n=18 studies, I2: 40%, Supplemental Figure 3, Central Illustration); 310 
no significant association was also showed between SFA intake and CVD mortality (HR: 0.96, 311 
95%CI: 0.84-1.11, p=0.643, n=9 studies, I2: 30%, Supplemental Figure 4). While we found a 312 
significant association with CHD mortality (HR: 1.10, 95%CI: 1.01-1.20, p<0.001, n=19 studies, 313 
I2: 52%, Figure 3, Central Illustration). No significant association was observed between SFA 314 
and stroke mortality (HR: 1.03, 95%CI: 0.85-1.26, p=0.703, n=3 studies, I2: 41%). 315 
There was an inverse association between MUFA consumption and risk of all-cause mortality 316 
(HR: 0.94, 95%CI: 0.89-0.99, p=0.028, n=15 studies, I2: 56%, Figure 4, Central Illustration), 317 
while there was an inverse however non-significant association between MUFA intake and CVD 318 
mortality (HR: 0.89, 95%CI: 0.77-1.03, p=0.120, n=13 studies, I2: 32%, Supplemental Figure 5), 319 
and CHD mortality (HR: 0.99, 95%CI: 0.89-1.10, p=0.896, n=9 studies, I2: 49%, Supplemental 320 
Figure 6, Central Illustration). Finally, we showed an inverse and significant association 321 
between MUFA intake and stroke mortality (HR: 0.80, 95%CI: 0.67-0.96, p=0.019, n=3 studies, 322 
I2: 0%). 323 
There was an inverse link between PUFA consumption and risk of all-cause mortality (HR: 324 
0.88, 95%CI: 0.83-0.94, p<0.001, n=14 studies, I2: 63%, Figure 5, Central Illustration), while 325 
no significant association between PUFA intake and CVD was observed (HR: 0.98, 95%CI: 0.85-326 
1.12, p=0.773, n=8 studies, I2: 47.4, Supplemental Figure 7) and CHD (HR: 0.96, 95%CI: 0.85-327 
1.07, p=0.480, n=8 studies, I2: 51.0, Supplemental Figure 8, Central Illustration) mortality was 328 
observed. There was an inverse significant effect of PUFA consumption on the risk of stroke 329 
mortality (HR: 0.84, 95%CI: 0.80-0.90, p<0.001, n=2 studies, I2: 0.0). 330 
 331 
Sensitivity analysis: 332 
In leave-one-out sensitivity analyses, the pooled effect estimates remained similar for the 333 
association of total fat (HR: 0.89, 95%CI: 0.82-0.97, p=0.009), SFA (HR: 1.03, 95%CI: 0.99-1.08, 334 
p=0.113), MUFA (HR: 0.93, 95%CI: 0.87-0.99, p=0.043) and PUFA (HR: 0.86, 95%CI: 0.80-335 
0.93, p<0.001) intake on all-cause mortality.  336 
 337 
Publication bias: 338 
Both Egger’s linear regression (intercept=0.461, 95%CI: -2.45, 3.37, p=0.523) and Begg’s 339 
rank correlation test (Kendall’s Tau with continuity correction=0.285, z=0.901, p=0.415) were not 340 
indicative of publication bias. After adjustment of effect size for potential publication bias using 341 
the ‘trim and fill’ correction, no potentially missing studies were imputed in funnel plot. The ‘fail-342 
safe N’ test showed that 126 studies would be needed to bring the weighted mean difference down 343 
to a non-significant (p≥0.05) value.  344 
 345 
DISCUSSION 346 
Using a large and representative samples of USA adults, with long follow-up periods we have 347 
found that reported total dietary fat intake is linked to lower all-cause mortality (10-13%). SFA 348 
intake was associated with all-cause, CHD, stroke and T2D mortality. In contrast, PUFA intake 349 
showed an inverse association; higher intake was associated with lower risk of all-cause and cause-350 
specific mortality. MUFA intake was not significantly associated with any type of mortality. These 351 
results were robust even after adjustments for a wide range of clinical, nutritional and socio-352 
economic factors. We further pooled data from all the published prospective studies with >1.1 353 
million participants; this confirmed the results based on NHANES cohort studies and revealed a 354 
protective association of total fat, MUFA and PUFA on all-cause mortality, while no link was 355 
observed between total fat, MUFA and PUFA intake with CVD and CHD mortality (with 356 
significant association with stroke mortality). SFA intake was associated with higher risk of CHD 357 
mortality. 358 
Currently, there are considerable discrepancies between studies regarding fat intake and its 359 
relationship with all-cause and cause-specific mortality 10,11,13,42-58. Our results showed an inverse 360 
association of all-cause mortality with total fat, MUFA and PUFA consumption. The PURE study 361 
(18 countries, n=135 335, follow-up of 7.4 years) study reported that intake of total fat and each 362 
type of fat was associated with lower risk of all-cause mortality (total fat: HR 0·77 [95% CI 0·67-363 
0·87]; saturated fat, HR 0·86 [0·76-0·99]; monounsaturated fat: HR 0·81 [0·71-0·92] and 364 
polyunsaturated fat: HR 0·80 [0·71-0·89]) 42. Another study that investigated 83,349 women from 365 
the Nurses’ Health Study (follow up of 32 years) and 42,884 men from the Health Professionals 366 
Follow-up Study (follow up of 26 years), reported that the HRs of all-cause mortality comparing 367 
extreme quartiles of specific dietary fats was 1.08, (95% CI: 1.03-1.14) for saturated fat, 0.81 (95% 368 
CI: 0.78-0.84) for polyunsaturated fat and 0.89 (95% CI: 0.84-0.94) for monounsaturated fat 11. In 369 
contrast, Wakai et al. 10 and Leosdottir et al. 13, reported no significant association between total 370 
fat consumption and risk of all-cause mortality. We reported small (6% lower risk) but potentially 371 
protective association of MUFA intake on all-cause mortality (significant in the meta-analysis with 372 
longer follow-up), which is in line with the PREvención con DIeta MEDiterránea study (n=7038, 373 
6 years follow-up) that reported inverse associations with all-cause death for PUFA and MUFA 374 
intakes 43. Further, the above-mentioned study by Wakai et al. (Japan Collaborative Cohort Study; 375 
58,672 individuals; 19.3-year follow up) found an inverse association between total fat intake and 376 
all-cause mortality (HR: 0.91, 95%CI:0.93-0.99) 10. Surprisingly, a recent meta-analysis of 49 377 
RCTs (but with fewer participants and a much shorter follow-up in comparison to our meta-378 
analysis) investigated the link between PUFA intake (PUFA supplementation, but not habitual 379 
PUFA intake) and mortality, and reported that increasing PUFA intake probably has little or no 380 
effect on all-cause mortality. In our study habitual PUFA intake was associated with lower all-381 
cause mortality by 14-19%. Furthermore, the investigators reported that increasing PUFA has little 382 
or no effect on CVD mortality (we also observed only 2% risk reduction in the meta-analysis) 59.    383 
We have shown that total fat, MUFA and PUFA consumption were not significantly 384 
associated with either CVD or CHD mortality. The Esrey et al. study (n=4546, follow-up 12 years,), 385 
reported no significant association between total fat and CHD (RR: 0.99, 95%CI: 0.95-1.03) 386 
mortality 45. Similar results were observed by Xu et al. in their study with 2938 subjects and 7.2-387 
year follow-up (RR: 0.77, 95%CI: 0.40-1.44) 51. With regard to MUFA intake and CVD mortality, 388 
most of the studies are in line with our results. A single study, conducted by Guasch-Ferré et al. 389 
(n=7038, 6 years of follow-up) reported a surprisingly large protective effect of MUFA 390 
consumption on CVD mortality (RR: 0.50, 95%CI: 0.30-0.80) 43, while the result of other available 391 
studies on the link between MUFA intake and CVD mortality no significant association was 392 
observed 10,42,44,47,50,59. We believe the effect of PUFA intake on CVD mortality requires further 393 
investigation, as the available studies have conflicting results, and most suggest no link 10,13,42,44. 394 
However, the same study by Guasch-Ferré et al. study again reported very protective effect of 395 
PUFA consumption on CVD mortality (RR: 0.68, 95%CI: 0.48-0.96) 43. 396 
We observed strong and significant association between SFA-intake and all-cause and cause-397 
specific mortality in two investigated cohorts of NHANES study but after pooling all the studies 398 
in meta-analysis, SFA intake was no longer related to all-cause mortality, but it was associated 399 
with 10% higher risk of CHD mortality. Several available studies reported no link between SFA 400 
intake and all-cause mortality 13,42,43,50,44,58. The Malmo Diet and Cancer Study (n=28,098, 6-year 401 
follow up) demonstrated no significant link between SFA and all-cause mortality (RR: 0.89, 402 
95%CI: 0.64-1.23) 13. The same results were observed in relatively small (n=501) the Baltimore 403 
Longitudinal Study of Aging (BLSA) with 18-year follow-up (RR: 1.16, 95%CI: 0.86-1.56) 58. 404 
The effect of SFA intake on CHD mortality has been already observed 45,51-53,61. A study in a Greek 405 
population (n=28,572, 4.5 years follow-up), reported a highly significant link (RR: 1.76, 95%CI: 406 
1.11-2.77) between SFA and CHD mortality 61. 407 
Our study has some strengths and limitations. Our observational study was based on a well-408 
known, long-term large population-based US cohort. The availability of detailed data on covariates 409 
allowed us to better control for confounding. In NHANES, we used a validated 24-h food recall 410 
method, and our data was collected by trained personnel in settings, which allow us to report health 411 
data accurately. Although 24-h recall methods may be prone to bias and confounding, alternatives 412 
such as food-frequency questionnaires are also subjective estimates. Dietary intake of nutrients is 413 
complex to measure, and no instrument is perfect. It has been suggested that combining 414 
questionnaire data with biomarker levels is an attractive alternative, but this adds complexity and 415 
expense to studies 62. Furthermore, we evaluated over 1.1 million subjects in our meta-analysis, 416 
pooling all the published studies to reinforce our cohort results. However, varying definitions of 417 
the exposure also pose a significant limitation to the interpretation and reliability of the meta-418 
analysis, which might be sensitive to the categorization of fat intake and the varying definitions. 419 
Heterogeneity of the results of the component studies was relatively low or modest, which 420 
indicated that each result was broadly consistent and most variation may be attributable to chance 421 
alone. The limitation of the cohort study is its observational design, which means we cannot 422 
exclude the possibility that our findings may be influenced by unmeasured or residual confounding 423 
factors or indeed reverse causality whereby ill health alters diet. Studies focusing on single 424 
nutrients can be complicated by the fact that a diet low in one energy source (e.g. fat) may contain 425 
higher amounts of alternative energy sources e.g. carbohydrate 63 but also that people 426 
(non)adherent to reduce one energy source, might be also (non)adherent to others (like proteins or 427 
carbohydrate). In the NHANES 1999-2010 results, an increase in BMI and in the percentage of 428 
obesity from Q1 to Q4 was observed, whereas this is not reflected by the energy intake. Although, 429 
our analysis was corrected for several covariates (however not all data was available, including 430 
details on medication used), it would be better for the future studies to consider more variables or 431 
use a different design to minimize the impact of other factors, as demographic details, risk factors 432 
and the gender balance of the participants varied between quartiles of fat intake in this analysis. 433 
As our analysis was based on quantities of fat, rather than specific foods, it is hard to interpret the 434 
results in terms of specific advice for patients. 435 
In conclusion, our results highlighted the divergent associations between total fat, MUFA and 436 
PUFA and all-cause mortality, while suggesting that not only quantity but also quality is critical 437 
for long-term outcomes. SFA intake was mainly associated with higher CHD mortality, and PUFA 438 
with significantly lower all-cause mortality and stroke events. No significant association was 439 
observed between total fat and MUFA with CVD and CHD mortality. Further well-design studies 440 
are necessary to explain all the inconsistencies between dietary fat intake and all-cause and cause-441 
specific mortality and to provide clear recommendations on target levels of fats in the healthy diet. 442 
For now, however, based on these data, and the results of prior trials, it seems sensible to focus on 443 
the quality of dietary fats with a reduction in SFA intake and increase PUFA and MUFA intake to 444 
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FIGURES LEGENDS: 461 
Central Illustration: An effect of total dietary fats, saturated, mono- and polyunsaturated fats on 462 
all-cause and CHD mortality based in NHANES and meta-analysis results.  463 
Figure 1: Risk of all-cause death across the category of total fat intake in NHANES 1999-2010 464 
Figure 2. Forest plot of total fat consumption and all-cause mortality. 465 
Figure 3. Forest plot of high-saturated fatty acids consumption and risk of coronary heart disease 466 
mortality. 467 
Figure 4. Forest plot of monounsaturated fatty acids consumption and risk of all-cause mortality. 468 
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Table 1.  Characteristics of the study participants based on total fat consumption (NHANES, 1999-2010). 
 Total Fat Consumption 
(NHANES 1999-2010) 
Q1 (n = 5996) Q2 (n = 6142) Q3 (n = 6008) Q4 (n = 5998) 
P-value Macronutrients’ amounts (g/day; 
calories/day; %energy*) 
Carbohydrate: 161 (644), 
Protein: 45 (180),             
Fat: 32 (288; 25%) 
Carbohydrate: 212 (848), 
Protein: 63 (252),             
Fat: 55 (495; 31%) 
Carbohydrate: 254 
(1016), Protein: 79 (316),                  
Fat: 80 (720; 35%) 
Carbohydrate: 328 (1312), 
Protein: 109 (436),            
Fat: 120 (1080; 38%) 
Age (Years) 51.2±0.2 48.2±0.2 45.6±0.1 40.8±0.2 <0.001 
Gender Men (%) 36.9 32.9 52.9 58.4 
<0.001 
Women (%) 63.1 67.1 47.1 41.6 
Race/Ethnicity Mexican-American 
(%) 
23.5 19.4 16.5 14.4 
<0.001 Non-Hispanic White 
(%) 
42.2 46.5 48.9 55.5 
Non-Hispanic Black 
(%) 
17.8 19.6 21.8 21.5 
Education level: <9th grade, (%) 15.6 14.3 12.5 8.5 <0.001 
Smoking (%) 22.3 21.0 25.8 23.6 <0.001 
Body Mass Index (kg/m2) 1 27.2±0.2 28.5±0.2 29.3±0.2 29.6±0.2 <0.001 
Diabetes (%) 9.0 10.6 12.4 13.2 <0.001 
Hypertension (%) 18.5 19.5 20.1 18.9 <0.001 
Obesity (%) 31.8 35.1 39.4 41.2 <0.001 
Metabolic syndrome (%) 29.1 31.2 32.3 30.5 <0.001 
Dietary cholesterol (g/day) 2 108.0 (66.0-173.0) 182.0 (124.0-285.0) 252.0 (176.0-392.0) 383.0 (263.5-594.0) <0.001 
Protein (g/day) 2 45.15 (32.67-59.72) 63.22 (50.48- 80.03) 79.59 (64.63-98.95) 109.68 (89.06 -137.36) <0.001 
Carbohydrate (g/day) 2 161.17 (117.57- 215.46) 212.57 (165.41-269.91) 254.77 (197.18-321.40) 328.01 (254.02 -421.27) <0.001 
Groups across the quartiles were compared by either chi-square or analysis of variance. Values expressed as mean ± standard error of mean 1 or median and (25th-75th) 2. 











Table 2.  Multivariable-adjusted hazard ratios (95% confidence intervals) for mortality across the categories of different fats in NHANES 1999-2010 study. 
  
Total Fat  SFA  
p-value  p-value 
Q2 Q3 Q4 Q2 Q3 Q4 
Total mortality Model 1 1.10 (0.58-2.13) 1.02 (0.29,3.96) 0.84 (0.81,0.88) 0.235 1.40 (1.35,1.57) 1.68 (1.61,1.75) 1.73 (1.66,1.80) <0.001 
Model 2 0.98 (0.50-1.90) 0.89 (0.84,0.95) 0.90 (0.82,0.99) 0.015 1.05 (1.02,1.08) 1.14 (1.10,1.19) 1.08 (1.04,1.11) <0.001 
CHD Model 1 1.03 (0.97, 1.09) 0.99 (0.95, 1.02) 0.88 (0.86,0.89) 0.292 1.02 (0.84, 1.24) 0.93 (0.77, 1.14) 1.42 (1.27,1.96) <0.001 
Model 2 1.13 (0.97, 1.31) 0.93 (0.79, 1.10) 1.07 (0.99,1.15) 0.421 1.09 (0.93, 1.29) 1.06 (1.03-1.09) 1.13 (1.06,1.21) <0.001 
Stroke Model 1 0.97 (0.91, 1.02) 1.01 (0.95, 1.08) 1.04 (0.96,1.12) 0.362 1.18 (0.95, 1.46) 0.88 (0.66, 1.17) 1.23 (1.11,1.43) 0.012 
Model 2 1·03 (0·78, 1·35) 1.24 (0.62,2.48) 1.05 (0.99,1.11) 0.665 1.02 (0.84, 1.22) 1.05 (1.02-1.08) 1.11 (1.07, 1.15) <0.001 
T2D Model 1 1·10 (0·84, 1·44) 1·06 (0·80, 1·39) 1·18 (0·90,1·56) 0.462 0.88 (0.73, 1.06) 0.97 (0.81, 1.17) 1.20 (1.11,1.36) 0.182 
Model 2 0.99 (0.97, 1.02) 0.98 (0.95, 1.01) 1·05 (0·77,1·43) 0.582 0.99 (0.77, 1.26) 1.05 (0.99, 1.12) 1.04 (1.01, 1.08) 0.241 
 MUFA  PUFA  
Q2 Q3 Q4 Q2 Q3 Q4 
Total mortality Model 1 1.02 (0.29,3.96) 0.85(0.80, 0.91) 0.71(0.69, 0.74) 0.024 0.95 (0.49-1.96) 0.72 (0.62-0.83) 0.68 (0.65-0.70) <0.001 
Model 2 0.98 (0.50,1.90) 0.93(0.79, 1.10) 0.91(0.76,1.09) 0.362 0.85 (0.79-0.91) 0.78 (0.72- 0.84) 0.81 (0.78-0.84) <0.001 
CHD Model 1 0.95 (0.59, 1.52) 0.93(0.59, 1.48) 1.04(0.84,1.29) 0.526 1.12 (0.52-1.35) 0·70 (0·60-0·82) 0.57 (0.55, 0.60) <0.001 
Model 2 0.91 (0.75, 1.11) 0.87(0.61,1.23) 0.95(0.77,1.17) 0.421 0.83 (0.77- 0.89) 0·87 (0·73-1·04) 0·75 (0·62-0·90) 0.016 
Stroke Model 1 1.04 (0.72,1.49) 0.82(0.51, 1.32) 0.86(0.53,1.40) 0.625 1.19 (0.93-1.53) 1.01 (0.91-1.11) 0·83 (0·72-0·96) 0.382 
Model 2 1.02 (0.64,1.64) 1.20(0.79, 1.83) 0.80(0.61,1.06) 0.692 0.96 (0.79-1.16) 0·81 (0·71-0·91) 0·85 (0·80-0.91) <0.001 
T2D Model 1 0.91 (0.57, 1.45) 0.84(0.66, 1.07) 0.88(0.73, 1.06) 0.452 0.96 (0.79, 1.17) 0.85 (0.79, 0.91) 0.78 (0.72,0.84) <0.001 
Model 2 0.94 (0.55, 1.59) 0.89(0.74, 1.06) 1.14(0.93, 1.39) 0.762 0.99 (0.77, 1.26) 0.88 (0.66, 1.17) 0.84 (0.79,0.92) 0.162 
Model 1: Adjusted for age, race, education, marital status, poverty to income ratio, physical activity and smoking. 
Model 2: Adjusted for age, race, education, marital status, poverty to income ratio, physical activity, smoking, alcohol consumption, dietary cholesterol, body mass index and hypertension, non-HDL cholesterol. 
ABBREVIATIONS: MUFA: mono-unsaturated fatty acids, SFA: saturated fatty acids, PUFA: polyunsaturated fatty acids, CHD: coronary heart disease, T2D: diabetes, HDL: high-density lipoprotein, NHANES: National 
Health and Nutrition Examination Surveys. 




Supplemental Table 1. Full search terms and strategy for papers indexed in investigated 
databases.  
No Concept Search terms 
1 Fat 
"Dietary fat" [Text Word] OR "fatty acids" [Text Word] OR 
"monounsaturated fat" [Text Word] OR "MUFA" [Text Word] OR 
"polyunsaturated fat" [Text Word] OR "PUFA" [Text Word] OR 
“unsaturated fatty acids" [Text Word] OR "SFA" OR “olive oil" 
[Text Word] OR "oleic acid" [Text Word] OR "Mediterranean 
diet" [Text Word] OR ω-3 FA” [Mesh] OR “omega-3 FA” [Mesh] 
OR “omega-3 OR “fish oils” [Mesh] 
2 Mortality 
mortality[tiab] OR death[tiab] OR dead[tiab] OR all-cause[tiab] 
OR all cause[tiab] OR fatal[tiab] OR event[tiab] OR nonfatal[tiab] 
OR non-fatal[tiab] OR Mortality[MeSH:NoExp] OR 
mortality[MeSH  subheading] 
3 Cardiovascular 
cardiovascular[tiab] OR vascular[tiab] OR CVD[tiab] OR 
Cardiovascular Diseases[Mesh:NoExp] 
4 Stroke 
cerebrovascular[tiab] OR stroke[tiab] OR TIA[tiab] OR transient 
ischemic*[tiab] OR CVA[tiab] OR cerebral infarction[tiab] OR 
Cerebrovascular accident [MeSH:NoExp]  OR stroke 
[MeSH:NoExp] 
5 Diabetes 
diabetes mellitus[MeSH Terms] OR diabetes OR mellitus OR 
diabetes mellitus OR diabetes mellitus, type 2[MeSH Terms] OR 
type 2 diabetes mellitus OR type 2 diabetes OR diabetes 
mellitus[MeSH Terms] OR diabetes AND mellitus OR diabetes 
mellitus OR diabetes OR diabetes insipidus[MeSH Terms] OR 
diabetes AND insipidus OR diabetes insipidus 





#1 AND #6 
8 Limit 
Rats[Mesh:NoExp]) OR Mice[Mesh:NoExp]) OR 
rat[Title/Abstract]) OR rats[Title/Abstract]) OR 
mouse[Title/Abstract]) OR mice[Title/Abstract]) OR 
vivo[Title/Abstract]) OR vitro[Title/Abstract]) 
9 Limit  #7 NOT #8 
For Supplemental Table 2: 
 
NEWCASTLE – OTTAWA QUALITY ASSESSMENT SCALE COHORT STUDIES 
 
Note: A study can be awarded a maximum of one star for each numbered item within the 
Selection and Outcome categories. A maximum of two stars can be given for Comparability.  
 
Selection  
1) Representativeness of the exposed cohort  
a) truly representative of the average healthy adults in the community   
b) somewhat representative of the average healthy adults in the community  
c) selected group of users e.g. nurses, volunteers, vegetarian 
d) no description of the derivation of the cohort  
2) Selection of the non-exposed cohort  
a) drawn from the same community as the exposed cohort   
b) drawn from a different source  
c) no description of the derivation of the non-exposed cohort  
3) Ascertainment of exposure  
a) secure record (e.g. 7 day food diary)   
b) structured interview/≥ 2 dietary recalls/diet history/ food frequency questionnaire validated 
for dairy components   
c) written self-report (e.g. <2 dietary recalls/non-validated food frequency questionnaire or not 
reported whether food frequency questionnaire was validated)  
d) no description  
4) Demonstration that outcome of interest was not present at start of study  
a) yes  
b) no  
 
Comparability  
1) Comparability of cohorts on the basis of the design or analysis  
a) study controls for age, sex, smoking, total energy intake, and body mass index  
b) study controls for any additional factor (e.g. physical activity, alcohol intake, family history of 
diabetes, dietary factors)  
 
Outcome  
1) Assessment of outcome  
a) independent blind assessment (e.g. clinical diagnosis/complete medical information available).
 
b) record linkage/medical record or validated self-report  
c) non-validated self-report 
d) no description  
2) Was follow-up long enough for outcomes to occur  
a) yes/ follow up period for outcome of interest is 10 years or over  
b) no  
3) Adequacy of follow-up of cohorts  
a) complete follow-up - all subjects accounted for   
b) subjects lost to follow-up unlikely to introduce bias - small number lost ≤20% follow-up, or 
description provided of those lost  
c) follow-up rate <80% or no description of those lost  



















Supplemental Table 2. Quality assessment of cohort studies which included in meta-analysis. 
Studies 


















of cohorts on 















Dilis 2012 (1) C A  B  A  A       B  B  B B  7 
Esrey 1996 (2) C  A  B  A  A  B  A  B  7 
Nagata 2012 
(3) C A  B  A  A       B  B  A  B  8 
Pietinen 1997 
(4) C  A  B  A  A  B  A  B  7 
Solfrizzi  
2005 (5) C A  B  A  A       B  B  A  B  8 
Trichopoulou 
2005 (6) C A  B  A  A       B  B  A  B  8 
Trichopoulou 
2003 (7) C A  B  A  A       B  B  A  B  8 
Xu 2006 (8)  C A  B  A  A       B  B  B B  7 
Ascherio 1996 
(9) 
C  A  B  A  A  B  A  B  7 




C A  B  A  A       B  B  A  B  8 
Leosdottir 
2005 (12) 
C A  B  A  A       B  B  A  B  8 
Mann 1997 
(13) 
C  A  B  A  A  B  A  B  7 
McGee 1985 
(14) 
C A  B  A  A       B  B  B B  7 
Sauvaget 2004 
(15) 
C A  B  A  A       B  B  B B  7 
Tucker 2005 
(16) 
C A  B  A  A       B  B  B B  7 
Misirli 2012 
(17) 
C A  B  A  A       B  B  B B  7 
Trichopoulou 
2006 (18)  
C  A  B  A  A  B  A  B  7 
Chien 
2013(19) 
C A  B  A  A       B  B  B B  7 
Wakai 2014 
(20) 
C A  B  A  A       B  B  B B  7 
Shekelle 1981 
(21) 
C  A  B  A  A  B  A  B  7 
Kushi 1985 
(22)  
C  A  B  A  A  B  A  B  7 
Dehghan 2017 
(23) 
C A  B  A  A       B  B  B B  7 
Guasch-Ferré 
2015 (24) 
C A  B  A  A       B  B  B B  7 
Wang 2017 
(25) 
C A  B  A  A       B  B  B B  7 
Zhuang 2019 
(26) 
C A  B  A  A       B  B  B B  7 
Zhuang 2019 
(27) 
C A  B  A  A       B  B  B B  7 
 


















the exposure Outcome Main confounders 
Dilis, 
2012 (1) 
European Prospective Into 
Cancer and Nutrition GRE 
20-86 10 240 23,929 MUFA, SFA, PUFA 




Age, BMI, height, PA, years of 
schooling and energy intake entered, 
alcohol consumption, smoking status 
and arterial blood pressure 
Esrey, 
1996 (2) 
Lipid Research Clinics 
Prevalence Study USA 
30-79 




1% increase in 
fatty acids intake CHD mortality 
Age, sex, energy intake, serum lipids, 
systolic blood pressure, cigarette 
smoking, BMI, glucose intolerance 
Nagata, 
2012 (3) 









Age, non-alcohol energy, and protein 
expressed as percentage of non-alcohol 
energy and was additionally adjusted 
for fat subtypes expressed as 
percentage of 
non-alcohol energy as appropriate, 
height, BMI, PA, smoking status, 
alcohol intake, education, marital 
status, menopausal status, histories of 
diabetes and hypertension, and intakes 





Cancer Prevention Study 
50-69 6.1 635 21,930 MUFA, SFA Q5 vs Q1 CHD mortality 
Age, smoking, BMI, blood pressure, 
energy 
intake, alcohol, education, PA 
Solfrizzi, 
2005 (5) 
Italian Longitudinal Study 
on Aging ITA 65-84 8.5 91 278 MUFA Not reported  
All-cause 
mortality 
Age, sex, waist-hip ratio, smoking 
status, Charlson co-morbidity index, 
and total energy intake 
Trichopoulo
u, 2005 (6) 
European Prospective Into 
Cancer and Nutrition 
Elderly EU 
>60 7.4 - 74,607 MUFA, PUFA, SFA Not reported  
All-cause 
mortality 
Age, sex, diabetes mellitus at baseline, 
waist to hip ratio, BMI, educational 
achievement, smoking status, PA at 
occupation, PA score at leisure, alcohol 
intake, and total energy intake 
Trichopoulo
u, 2003 (7) 
European Prospective Into 
Cancer and Nutrition GRE 
20-86 3.7 275 22,043 MUFA, PUFA, SFA 





Age, sex, waist-to-hip ratio, energy 
expenditure score, years of education, 
smoking status, BMI, and total energy 
intake 
Xu, 2006 







Age, sex, energy, study centre, diabetes 
status, BMI, HDL, LDL, 
triacylglycerol, 
Smoking, alcohol consumption, 
hypertension, percentage of energy 













 - Q5 vs. Q1 CHD Deaths 
Age, energy, BMI, smoking habits, 
alcohol consumption, physical activity, 
history of hypertension or high blood 
cholesterol, family history of MI <60-










 Total, SFA Q5 vs. Q1  CHD Deaths 
Age, alcohol consumption, smoking 
habits, frequency of exercise, BMI, 





Israel 40+ 23  
3473, 
1098 11,876 
- Q5 vs. Q1 Total deaths and CHD 
deaths 













Q4 vs. Q1 Total and CVD deaths 
Age, alcohol, smoking, social class, 
marital status, physical activity, BMI, 
fibre intake, monounsaturated and 
polyunsaturated fats, total fat intake for 




United Kingdom 16-79 13.3  64, 392 10,802 
SFA Q3 vs. Q1 CHD deaths, all-cause 
mortality Age, sex, smoking habit, social class 
McGee, 
1985 (14) 
United States Honolulu 
Heart Program 45-60+ 10 
542; 61, 
99 7,088 
SFA ≥50 g vs. <10g SFA Total deaths; stroke deaths; CHD deaths 




Japan Adult Health Study 
(subcohort of the Life Span 
Study) 




Q3 vs Q1 Stroke deaths 
Radiation dose, city of exposure, 
smoking and drinking status, BMI, 
history of hypertension and diabetes, 
fruit and vegetable intake, markers of 
nutritional status, lymphocyte count, 




United States  Baltimore 
Longitudinal Study of 
Aging 
34-80 18 71 501 SFA Not reported CHD deaths 
Age at first visit, total energy intake, 
BMI, smoking, alcohol use, dietary 





into Cancer and Nutrition 
(EPIC Study), Greek-EPIC 
Cohort 




increments Stroke deaths 
Sex, age, smoking status, BMI, 
education, physical activity level, 
energy intake, hypertension, diabetes 
mellitus, Mediterranean diet score 
Trichopoulo
u, 2006 (18) 
Greece European 
Prospective Investigation 
into Cancer and Nutrition 
(EPIC Study), Greek-EPIC 
Cohort 
NR 4.5 80 1013  
MUFA, 
SFA, PUFA Not reported CVD deaths 
Gender, age, educational level, 
smoking, waist-to-height, hip 
circumference, physical activity, 
metabolic activity task score, total 
energy intake, treatment with insulin, 
treatment for hypertension at 
enrolment, treatment for 
hypercholesterolaemia at enrolment, 
flour, flakes, starches, pasta, rice, other 
grain, bread, crisp bread, rusks, 




Japan (Chin-Shan) ≈60 ≈10 568 3,602 SFA 
56.3% vs. 45% 
of total fat Total deaths 
Age, gender, BMI, smoking, drinking, 
marital status, education level, job and 
sports activity, hypertension, diabetes, 
LDL-C and HDL-C 
Wakai, 
2014 (20) 
Japan Collaborative Cohort 








7.3 vs. 3.0% E 
for SFA Total and CVD death 
Age, area, education, smoking, alcohol 
consumption, BMI, sleep duration, 
walking, consumption of vegetables 




U.S.A. (Western Electric 












SFA Top 3rd vs. Bottom 3rd CHD deaths Age, cohort, SBP, serum cholesterol, LVH, smoking, alcohol 
Dehghan, 
2017 (23) 
The Prospective Urban 




Q5 vs. Q1 Total deaths and CVD deaths 
Age and sex, education, smoking, 
physical activity, waist to hip ratio, 
history of diabetes, urban or rural 




PREvención con DIeta 




Q5 vs. Q1 Total deaths and CVD deaths 
Age, sex, total energy intake, alcohol 
intake, fiber, protein intake, BMI, 
smoking status, educational level, 
leisure-time physical activity, baseline 
diabetes, hypertension, 
hypercholesterolemia, family history of 




Nurses’ Health Study and 
the Health Professionals 
Follow-up Study - 







Q4 vs. Q1 Total deaths 
Age, Caucasian, marital status body-
mass index, physical activity, smoking 
status, alcohol consumption, 
multivitamin use, vitamin E 
supplementation use, current aspirin 
use, family history of myocardial 
infarction, family history of diabetes, 
family history of cancer, history of 
hypertension, history of 
hypercholesterolemia, intakes of total 
energy, dietary cholesterol and 
percentage of energy intake from 
dietary protein, and menopausal status 
and hormone use in women. 
Zhuang, 
2019 (26) 
China Health and Nutrition 
Survey - 14 1,007 14,117 PUFA Q4 vs. Q1 Total deaths 
Age, gender, BMI, education, marital 
status, residence, physical activity, 
smoking, alcohol drinking status, 
history of hypertension, history of 
diabetes, intake of total energy, 




NIH-AARP Diet and  
Health Study 50-71 16 129,328 521,120 
MUFA, 
PUFA, SFA Q4 vs. Q1 CVD, Total, T2D, 
Multivariable models were adjusted for 
age, gender, BMI, race, education, 
marital status, household income, 
smoking, alcohol, physical activity, 
multi-vitamin use, aspirin use, history 
of hypertension, history of 
hypercholesterolemia, perceived health 
condition, history of heart disease, 
stroke, diabetes, and cancer at baseline, 
hormones use for women, intake of 
total energy, percentages of energy 
intake from protein, and remaining 
fatty acids where appropriate. 
* Mazidi NHANES cohort study from the recent paper.   
 
REFERENCES (FOR SUPPLEMENTAL TABLES 2 & 3): 
1. Dilis V, Katsoulis M, Lagiou P, Trichopoulos D, Naska A, Trichopoulou A. Mediterranean diet and CHD: the Greek European 
Prospective Investigation into Cancer and Nutrition cohort. The British journal of nutrition. 2012;108(4):699-709. 
2. Esrey KL, Joseph L, Grover SA. Relationship between dietary intake and coronary heart disease mortality: lipid research clinics 
prevalence follow-up study. Journal of clinical epidemiology. 1996;49(2):211-6. 
3. Nagata C, Nakamura K, Wada K, Oba S, Tsuji M, Tamai Y, et al. Total fat intake is associated with decreased mortality in Japanese men 
but not in women. The Journal of nutrition. 2012;142(9):1713-9. 
4. Pietinen P, Ascherio A, Korhonen P, Hartman AM, Willett WC, Albanes D, et al. Intake of fatty acids and risk of coronary heart disease in 
a cohort of Finnish men. The Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study. American journal of epidemiology. 1997;145(10):876-
87. 
5. Solfrizzi V, D'Introno A, Colacicco AM, Capurso C, Palasciano R, Capurso S, et al. Unsaturated fatty acids intake and all-causes 
mortality: a 8.5-year follow-up of the Italian Longitudinal Study on Aging. Experimental gerontology. 2005;40(4):335-43. 
6. Trichopoulou A, Orfanos P, Norat T, Bueno-de-Mesquita B, Ocke MC, Peeters PH, et al. Modified Mediterranean diet and survival: 
EPIC-elderly prospective cohort study. BMJ (Clinical research ed). 2005;330(7498):991. 
7. Trichopoulou A, Costacou T, Bamia C, Trichopoulos D. Adherence to a Mediterranean diet and survival in a Greek population. The New 
England journal of medicine. 2003;348(26):2599-608. 
8. Xu J, Eilat-Adar S, Loria C, Goldbourt U, Howard BV, Fabsitz RR, et al. Dietary fat intake and risk of coronary heart disease: the Strong 
Heart Study. The American journal of clinical nutrition. 2006;84(4):894-902. 
9. Ascherio A, Rimm EB, Giovannucci EL, Spiegelman D, Stampfer M, Willett WC. Dietary fat and risk of coronary heart disease in men: 
cohort follow up study in the United States. BMJ (Clinical research ed). 1996;313(7049):84-90. 
10. Boniface DR, Tefft ME. Dietary fats and 16-year coronary heart disease mortality in a cohort of men and women in Great Britain. 
European journal of clinical nutrition. 2002;56(8):786-92. 
11. Goldbourt U, Yaari S, Medalie JH. Factors predictive of long-term coronary heart disease mortality among 10,059 male Israeli civil 
servants and municipal employees. A 23-year mortality follow-up in the Israeli Ischemic Heart Disease Study. Cardiology. 1993;82(2-3):100-21. 
12. Leosdottir M, Nilsson PM, Nilsson JA, Mansson H, Berglund G. Dietary fat intake and early mortality patterns--data from The Malmo 
Diet and Cancer Study. Journal of internal medicine. 2005;258(2):153-65. 
Mazidi, 
2019* 
 United States NHANES; 




Q4 vs. Q1 Total, CHD, stroke, T2D 
Age, race, education, marital status, 
poverty to income ratio, physical 
activity and smoking, alcohol 
consumption, dietary cholesterol, body 
mass index, hypertension, and non-
HDL cholesterol 
13. Mann JI, Appleby PN, Key TJ, Thorogood M. Dietary determinants of ischaemic heart disease in health conscious individuals. Heart 
(British Cardiac Society). 1997;78(5):450-5. 
14. McGee D, Reed D, Stemmerman G, Rhoads G, Yano K, Feinleib M. The relationship of dietary fat and cholesterol to mortality in 10 
years: the Honolulu Heart Program. International journal of epidemiology. 1985;14(1):97-105. 
15. Sauvaget C, Nagano J, Hayashi M, Yamada M. Animal protein, animal fat, and cholesterol intakes and risk of cerebral infarction mortality 
in the adult health study. Stroke. 2004;35(7):1531-7. 
16. Tucker KL, Hallfrisch J, Qiao N, Muller D, Andres R, Fleg JL. The combination of high fruit and vegetable and low saturated fat intakes 
is more protective against mortality in aging men than is either alone: the Baltimore Longitudinal Study of Aging. The Journal of nutrition. 
2005;135(3):556-61. 
17. Misirli G, Benetou V, Lagiou P, Bamia C, Trichopoulos D, Trichopoulou A. Relation of the traditional Mediterranean diet to 
cerebrovascular disease in a Mediterranean population. American journal of epidemiology. 2012;176(12):1185-92. 
18. Trichopoulou A, Psaltopoulou T, Orfanos P, Trichopoulos D. Diet and physical activity in relation to overall mortality amongst adult 
diabetics in a general population cohort. Journal of internal medicine. 2006;259(6):583-91. 
19. Chien KL, Lin HJ, Hsu HC, Chen PC, Su TC, Chen MF, et al. Comparison of predictive performance of various fatty acids for the risk of 
cardiovascular disease events and all-cause deaths in a community-based cohort. Atherosclerosis. 2013;230(1):140-7. 
20. Wakai K, Naito M, Date C, Iso H, Tamakoshi A. Dietary intakes of fat and total mortality among Japanese populations with a low fat 
intake: the Japan Collaborative Cohort (JACC) Study. Nutrition & metabolism. 2014;11(1):12. 
21. Shekelle RB, Shryock AM, Paul O, Lepper M, Stamler J, Liu S, et al. Diet, serum cholesterol, and death from coronary heart disease. The 
Western Electric study. The New England journal of medicine. 1981;304(2):65-70. 
22. Kushi LH, Lew RA, Stare FJ, Ellison CR, el Lozy M, Bourke G, et al. Diet and 20-year mortality from coronary heart disease. The 
Ireland-Boston Diet-Heart Study. The New England journal of medicine. 1985;312(13):811-8. 
23. Dehghan M, Mente A, Zhang X, Swaminathan S, Li W, Mohan V, et al. Associations of fats and carbohydrate intake with cardiovascular 
disease and mortality in 18 countries from five continents (PURE): a prospective cohort study. Lancet (London, England). 2017;390(10107):2050-
62. 
24. Guasch-Ferre M, Babio N, Martinez-Gonzalez MA, Corella D, Ros E, Martin-Pelaez S, et al. Dietary fat intake and risk of cardiovascular 
disease and all-cause mortality in a population at high risk of cardiovascular disease. The American journal of clinical nutrition. 
2015;102(6):1563-73. 
25. Wang DD, Li Y, Chiuve SE, Stampfer MJ, Manson JE, Rimm EB, et al. Association of Specific Dietary Fats With Total and Cause-
Specific Mortality. JAMA internal medicine. 2016;176(8):1134-45. 
26. Zhuang P, Wang W, Wang J, Zhang Y, Jiao J. Polyunsaturated fatty acids intake, omega-6/omega-3 ratio and mortality: Findings from 
two independent nationwide cohorts. Clinical nutrition (Edinburgh, Scotland). 2019;38(2):848-855. 
27.  Zhuang P, Zhang Y, He W, Chen X, Chen J, He L, Mao L, Wu F, Jiao J. Dietary Fats in Relation to Total and Cause-Specific Mortality in 
a Prospective Cohort of 521 120 Individuals With 16 Years of Follow-Up. Circ Res. 2019;124(5):757-768.  
 
 

















































Records after duplicates removed: 1742 
Records screened: 1742 
Records excluded based on title: 1690 
Full-text articles assessed: 52 
Full-text articles excluded, with reasons: 
1. Non-human, Genetics, Molecular 
2. Review and Conference data 
3. Editorials not related to our aim 
4. Not enough data 
Studies included in the systematic review: 29 













Study name Statistics for each study Hazard ratio and 95% CI
Hazard Lower Upper 
ratio limit limit p-Value
Nagata, 2012, M 1.120 0.799 1.569 0.510
Nagata, 2012, F 1.310 0.944 1.818 0.106
Wakai, 2014, M 1.050 0.890 1.239 0.564
Wakai, 2014, F 0.970 0.828 1.137 0.707
Guasch-Ferr,2015 0.580 0.391 0.861 0.007
Dehghan, 2017 0.920 0.725 1.168 0.493
Leosdottir, 2005, M 0.650 0.450 0.939 0.022
Leosdottir, 2005, F 0.740 0.401 1.364 0.335
0.928 0.797 1.082 0.340
0.5 1 2
Favours A Favours B
Meta Analysis
Meta Analysis
  Lower risk      Higher risk 
     
Overall: 













Study name Statistics for each study Hazard ratio and 95% CI
Hazard Lower Upper 
ratio limit limit p-Value
Mann (1997) 1.060 0.801 1.402 0.683
Tucker (2005) 1.160 0.861 1.562 0.329
Chien (2013) 1.330 1.010 1.751 0.042
Wakai (2014) F 0.910 0.829 0.999 0.047
Wakai (2014) M 0.980 0.899 1.069 0.647
Dehghan (2017) 0.860 0.757 0.977 0.020
Guasch-Ferr (2015) 1.080 0.739 1.578 0.691
Wang (2016) 1.080 1.022 1.142 0.007
Mazid (2018) 1.080 1.041 1.121 0.000
Nagata, 2012, M 0.850 0.701 1.031 0.099
Nagata, 2012, F 1.230 1.004 1.506 0.045
Wang, 2017, A 1.070 0.998 1.147 0.058
Wang, 2017, B 1.090 1.008 1.178 0.030
Trichopoulou, 2005 1.070 1.021 1.121 0.005
Trichopoulou, 2003 1.050 0.893 1.234 0.554
Leosdottir , 2005, M 0.910 0.693 1.195 0.498
Leosdottir ,2005, F 0.890 0.642 1.234 0.484
Zhoung, 2018 (UP) 1.290 1.251 1.331 0.000
1.049 0.985 1.118 0.139
0.5 1 2
Favours A Favours B
Meta Analysis
Meta Analysis
Lower risk      Higher risk 
  Overall: 
Supplemental Figure 4. Forest plot of saturated fatty acids (SFA) consumption and 











Study name Statistics for each study Hazard ratio and 95% CI
Hazard Lower Upper 
ratio limit limit p-Value
Sauvaget (2004) 0.580 0.280 1.201 0.142
Leosdottir ,2005, F 0.940 0.579 1.527 0.803
Leosdottir ,2005, M 0.550 0.259 1.167 0.119
Wakai, M (2014) 0.930 0.788 1.097 0.390
Wakai, F (2014) 0.990 0.842 1.163 0.903
Guasch-Ferr (2015) 1.810 1.048 3.125 0.033
Nagata, 2012, M 0.960 0.667 1.383 0.826
Nagata, 2012, F 1.280 0.913 1.795 0.153
Dehghan, 2017 0.830 0.647 1.065 0.143
0.968 0.842 1.112 0.643
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Supplemental Figure 5. Forest plot of monounsaturated fatty acids (MUFA) consumption and 











Study name Statistics for each study Hazard ratio and 95% CI
Hazard Lower Upper 
ratio limit limit p-Value
Dilis, 2012 1.240 0.475 3.236 0.660
Misisrli, 2012 0.610 0.351 1.062 0.080
Xu, 2006 1.250 0.260 6.010 0.781
Guasch-Ferr, 2015 0.500 0.309 0.808 0.005
Nagata, 2012, M 0.920 0.589 1.437 0.714
Nagata, 2012, F 1.280 0.847 1.935 0.242
Dehghan, 2017 0.850 0.661 1.092 0.204
Wakai, 2014, M 0.990 0.839 1.168 0.905
Wakai, 2014, F 0.940 0.802 1.102 0.446
Leosdottir, 2005, M 0.610 0.361 1.032 0.065
Leosdottir, 2005, F 1.530 0.647 3.621 0.333
0.892 0.772 1.030 0.120
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Supplemental Figure 6. Forest plot of monounsaturated fatty acids (MUFA) consumption and 











Study name Statistics for each study Hazard ratio and 95% CI
Hazard Lower Upper 
ratio limit limit p-Value
Pietinen, 1997 0.820 0.660 1.019 0.074
Mazid, 2018 0.950 0.771 1.171 0.631
Dillis, 2012, M 0.990 0.587 1.671 0.970
Dillis, 2012, F 1.460 0.623 3.424 0.384
Esrey, 1996, A 1.080 1.008 1.157 0.029
Esrey, 1996, B 1.000 0.923 1.083 1.000
Xu, 2006, A 3.430 1.165 10.098 0.025
Xu, 2006, B 0.540 0.273 1.070 0.077
Trichopoulou, 2006 1.040 0.658 1.644 0.867
0.993 0.895 1.102 0.896
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Supplemental Figure 7. Forest plot of polyunsaturated fatty acids (PUFA) consumption and 












Study name Statistics for each study Hazard ratio and 95% CI
Hazard Lower Upper 
ratio limit limit p-Value
Nagata, 2012, M 1.340 0.884 2.030 0.167
Nagata, 2012, F 1.090 0.749 1.587 0.653
Guasch-Ferr, 2015 0.680 0.481 0.962 0.029
Dehghan, 2017 0.940 0.764 1.156 0.558
Wakai, 2014, M 1.180 0.989 1.408 0.067
Wakai, 2014, F 0.930 0.788 1.097 0.390
Leosdottir, 2005, M 0.990 0.645 1.519 0.963
Leosdottir, 2005, F 0.630 0.328 1.211 0.166
0.980 0.851 1.127 0.773
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  Overall: 
Supplemental Figure 8. Forest plot of polyunsaturated fatty acids (PUFA) consumption and 




Study name Statistics for each study Hazard ratio and 95% CI
Hazard Lower Upper 
ratio limit limit p-Value
Dillis, 2012, M 0.900 0.685 1.182 0.449
Dillis, 2012, F 0.940 0.579 1.527 0.803
Esrey, 1996, A 0.990 0.904 1.084 0.829
Esrey, 1996, B 1.000 0.900 1.111 1.000
Xu, 2006, A 1.470 0.548 3.944 0.444
Xu, 2006, B 0.690 0.350 1.360 0.284
Trichopoulou, 2006 1.300 0.998 1.693 0.052
Mazidi, 2018 0.750 0.622 0.904 0.002
0.960 0.858 1.075 0.480
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  Overall: 
 
